Foundation Medicine Appoints Medical Oncologist Vincent A. Miller, M.D., as Senior Vice President of Clinical Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., a cancer diagnostics company that brings comprehensive cancer genome analysis to routine care, today announced the appointment of Vincent A. Miller, M.D., to the position of senior vice president of clinical development. In this role, Dr. Miller will be responsible for driving clinical strategy to support and expand the use of Foundation Medicine’s comprehensive cancer genomic test and will contribute to the ongoing development of the company’s data reporting platform and physician interface.

Dr. Miller joins Foundation Medicine from Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, where he served as attending physician and member. He brings nearly 20 years of experience in clinical and translational oncology in research and patient care to Foundation Medicine.

“We are thrilled to welcome Vince to our exceptional and growing leadership team at Foundation Medicine,” said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine. “As a board-certified medical oncologist and internist and a thought leader in research and development efforts of molecular targeted therapies, Vince brings a unique and invaluable insight to our ongoing efforts. His commitment to the treatment of patients with lung cancer, his dedication to furthering the understanding of molecular medicine and cancer biology, and his passion for incorporating molecular profiling to improve care for all cancer patients are critical assets to our team as we continue to expand the use of our comprehensive genomic test for cancer.”

Dr. Miller has been the recipient of a number of honors and awards over the course of his medical career, including his upcoming recognition by the Bonnie J. Addario Lung Cancer Foundation with the Thierry Jahan “A Breath Away from the Cure” award for his efforts and contributions to lung cancer research. The award will be presented on November 5 at the foundation’s “Simply The Best VI” Gala in San Francisco. Dr. Miller’s work in clinical and translational research in lung cancer culminated in observations and collaborative efforts critical to identification of EGFR sensitizing and resistance mutations.

He is considered a world expert in lung cancer and clinical trial design and interpretation and has authored or co-authored articles appearing in journals such as Proceedings of the National Academy of Science, Journal of the Public Library of Science, Cancer Research, Clinical Cancer Research, andthe Journal of Clinical Oncology. He is Fellow, American College of Physicians, and a member of American Association for Cancer Research, the American Society for Clinical Oncology and the International Association of the Study of Lung Cancer.

“This is an exciting time for those of us in oncology because we are finally seeing molecular medicine converge with clinical care and research, and we are beginning to better understand the power that convergence will bring to the care of patients living with cancer,” said Dr. Miller. “I believe that Foundation Medicine’s comprehensive genomic test, which assesses an unprecedented number of genomic changes from a small biopsy, will accelerate the discovery of new targets to improve cancer treatment, improve access to genomic testing for cancer patients, and ultimately improve outcomes for patients living with cancer. I am excited to be a part of the team and the continued efforts at Foundation Medicine to bring this test into routine clinical practice.”

Dr. Miller received his B.A. from the University of Pennsylvania and his M.D. from the University of Medicine and Dentistry of New Jersey. He completed his residency at the Thomas Jefferson University Hospital and his fellowship at the Memorial Sloan-Kettering Cancer Center.

About Foundation Medicine

Foundation Medicine is dedicated to improving cancer care through the development of comprehensive cancer diagnostics that will help physicians inform treatment decisions based on an individual patient’s molecular cancer subtype. Foundation Medicine’s first laboratory test, based on a targeted, massively parallel sequencing platform, is designed to accommodate a broad landscape of cancer genome information and a growing repertoire of targeted treatments and clinical research opportunities. Foundation Medicine’s test will assist physicians to make prompt and informed determinations about the best cancer treatments and clinical trial options for each patient, taking into account each patient’s unique cancer-associated alterations alongside publicly available scientific and medical information. The company’s founding advisors are world leaders in genome technology, cancer biology and medical oncology; they, alongside clinicians and biotech and molecular diagnostics industry leaders, are working to harness emerging technologies to develop unparalleled tests that will identify and interpret an ever-growing set of actionable genomic alterations, truly enabling personalized cancer medicine. For more information, please visit the company’s website at www.foundationmedicine.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20111102005578/en/Foundation-Medicine-Appoints-Medical-Oncologist-Vincent-A.

Foundation Medicine Contact: Lee-Ann Murphy, 617-245-3077
pr@foundationmedicine.com

Source: Foundation Medicine